Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, Klarenbach S, Gill J (2011) Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 11(10):2093–2109. https://doi.org/10.1111/j.1600-6143.2011.03686.x

Article  CAS  PubMed  Google Scholar 

Thongprayoon C, Hansrivijit P, Leeaphorn N, Acharya P, Torres-Ortiz A, Kaewput W, Kovvuru K, Kanduri SR, Bathini T, Cheungpasitporn W (2020) Recent advances and clinical outcomes of kidney transplantation. J Clin Med. https://doi.org/10.3390/jcm9041193

Article  PubMed  PubMed Central  Google Scholar 

KDIGO CKD–MBD Update Work Group (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011) 7(1):1–59. https://doi.org/10.1016/j.kisu.2017.04.001

Article  Google Scholar 

Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69(11):1945–1953. https://doi.org/10.1038/sj.ki.5000414

Article  CAS  PubMed  Google Scholar 

Mace ML, Egstrand S, Morevati M, Olgaard K, Lewin E (2021) New insights to the crosstalk between vascular and bone tissue in chronic kidney disease–mineral and bone disorder. Metabolites. https://doi.org/10.3390/metabo11120849

Article  PubMed  PubMed Central  Google Scholar 

Vangala C, Pan J, Cotton RT, Ramanathan V (2018) Mineral and bone disorders after kidney transplantation. Front Med (Lausanne) 5:211. https://doi.org/10.3389/fmed.2018.00211

Article  PubMed  Google Scholar 

Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y (2007) Tertiary ‘hyperphosphatoninism’ accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 7(5):1193–1200. https://doi.org/10.1111/j.1600-6143.2007.01753.x

Article  CAS  PubMed  Google Scholar 

Figurek A, Rroji M, Spasovski G (2020) Sclerostin: a new biomarker of CKD–MBD. Int Urol Nephrol 52(1):107–113. https://doi.org/10.1007/s11255-019-02290-3

Article  PubMed  Google Scholar 

Tartaglione L, Pasquali M, Rotondi S, Muci ML, Leonangeli C, Farcomeni A, Fassino V, Mazzaferro S (2017) Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation. PLoS ONE 12(5):e0178637. https://doi.org/10.1371/journal.pone.0178637

Article  CAS  PubMed  PubMed Central  Google Scholar 

Basir H, Altunoren O, Erken E, Kilinc M, Sarisik FN, Isiktas S, Gungor O (2019) Relationship between osteoporosis and serum sclerostin levels in kidney transplant recipients. Exp Clin Transplant. https://doi.org/10.6002/ect.2019.0022

Article  PubMed  Google Scholar 

Hsu BG, Liou HH, Lee CJ, Chen YC, Ho GJ, Lee MC (2016) Serum sclerostin as an independent marker of peripheral arterial stiffness in renal transplantation recipients: a cross-sectional study. Medicine (Baltim) 95(15):e3300. https://doi.org/10.1097/md.0000000000003300

Article  Google Scholar 

Evenepoel P, Claes K, Viaene L, Bammens B, Meijers B, Naesens M, Sprangers B, Kuypers D (2016) Decreased circulating sclerostin levels in renal transplant recipients with persistent hyperparathyroidism. Transplantation 100(10):2188–2193. https://doi.org/10.1097/tp.0000000000001311

Article  CAS  PubMed  Google Scholar 

Magalhães J, Quelhas-Santos J, Pereira L, Neto R, Castro-Ferreira I, Martins S, Frazão JM, Carvalho C (2022) Could bone biomarkers predict bone turnover after kidney transplantation? A proof-of-concept study. J Clin Med. https://doi.org/10.3390/jcm11020457

Article  PubMed  PubMed Central  Google Scholar 

Ferreira AC, Cotovio P, Aires I, Mendes M, Navarro D, Silva C, Caeiro F, Salvador R, Correia B, Cabral G, Nolasco F, Ferreira A (2022) The role of bone volume, FGF23 and sclerostin in calcifications and mortality; a cohort study in CKD stage 5 patients. Calcif Tissue Int 110(2):215–224. https://doi.org/10.1007/s00223-021-00910-8

Article  CAS  PubMed  Google Scholar 

Wang YP, Sidibé A, Fortier C, Desjardins MP, Ung RV, Kremer R, Agharazii M, Mac-Way F (2023) Wnt/β-catenin pathway inhibitors, bone metabolism and vascular health in kidney transplant patients. J Nephrol 36(4):969–978. https://doi.org/10.1007/s40620-022-01563-y

Article  CAS  PubMed  Google Scholar 

Evenepoel P, Goffin E, Meijers B, Kanaan N, Bammens B, Coche E, Claes K, Jadoul M (2015) Sclerostin serum levels and vascular calcification progression in prevalent renal transplant recipients. J Clin Endocrinol Metab 100(12):4669–4676. https://doi.org/10.1210/jc.2015-3056

Article  CAS  PubMed  Google Scholar 

Koh HB, Ryu JH, Kim SS, Kim MG, Park JB, Kim CD, Kang KP, Ro H, Han SY, Huh KH, Yang J (2023) Association between sclerostin levels and vascular outcomes in kidney transplantation patients. J Nephrol 36(7):2091–2109. https://doi.org/10.1007/s40620-023-01732-7

Article  CAS  PubMed  Google Scholar 

Zeng S, Slowinski T, Pommer W, Hasan AA, Gaballa MMS, Lu Y, Krämer BK, Hocher B (2020) Sclerostin is an independent risk factor for all-cause mortality in kidney transplant recipients. Clin Exp Nephrol 24(12):1177–1183. https://doi.org/10.1007/s10157-020-01956-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coban M, Okten S (2020) The correlation between sclerostin and bone mineral density in renal transplant recipients. Nefrologia (Engl Ed) 40(5):506–513. https://doi.org/10.1016/j.nefro.2020.04.009

Article  PubMed  Google Scholar 

Ferreira AC, Mendes M, Silva C, Cotovio P, Aires I, Navarro D, Caeiro F, Salvador R, Correia B, Cabral G, Nolasco F, Ferreira A (2021) Bone densitometry versus bone histomorphometry in renal transplanted patients: a cross-sectional study. Transplant Int 34(6):1065–1073. https://doi.org/10.1111/tri.13888

Article  CAS  Google Scholar 

Venner JM, Hidalgo LG, Famulski KS, Chang J, Halloran PF (2015) The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Am J Transplant 15(5):1336–1348. https://doi.org/10.1111/ajt.13115

Article  CAS  PubMed  Google Scholar 

Ferreira AC, Mendes M, Silva C, Cotovio P, Aires I, Navarro D, Caeiro F, Ramos R, Salvador R, Correia B, Cabral G, Nolasco F, Ferreira A (2022) Improvement of mineral and bone disorders after renal transplantation. Transplantation 106(5):e251–e261. https://doi.org/10.1097/tp.0000000000004099

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonani M, Rodriguez D, Fehr T, Mohebbi N, Brockmann J, Blum M, Graf N, Frey D, Wüthrich RP (2014) Sclerostin blood levels before and after kidney transplantation. Kidney Blood Press Res 39(4):230–239. https://doi.org/10.1159/000355781

Article  CAS  PubMed  Google Scholar 

Evenepoel P, Claes K, Meijers B, Laurent MR, Bammens B, Naesens M, Sprangers B, Pottel H, Cavalier E, Kuypers D (2019) Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. Kidney Int 95(6):1461–1470. https://doi.org/10.1016/j.kint.2018.12.024

Article  PubMed  Google Scholar 

Marques IDB, Araújo M, Graciolli FG, Dos Reis LM, Pereira RMR, Alvarenga JC, Custódio MR, Jorgetti V, Elias RM, Moysés RMA, David-Neto E (2019) A randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation. J Am Soc Nephrol 30(2):355–365. https://doi.org/10.1681/asn.2018060656

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brandenburg VM, Verhulst A, Babler A, D’Haese PC, Evenepoel P, Kaesler N (2019) Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Nephrol Dial Transplant 34(3):408–414. https://doi.org/10.1093/ndt/gfy129

Article  CAS  PubMed  Google Scholar 

Elder GJ (2016) Decreased circulating sclerostin levels in renal transplant recipients with persistent hyperparathyroidism: who’s conducting the orchestra? Transplantation 100(10):2016–2017. https://doi.org/10.1097/tp.0000000000001312

Article  PubMed  Google Scholar